Tag: pharmaceuticals
-
NIH Giving In-Kind Technical Services for Rare Diseases
National Institutes of Health (NIH) is supporting three new projects with technical research services for two companies and one university lab developing therapies for rare diseases. The projects aim to develop treatments for acute radiation syndrome, brain injury following cardiac arrest, and beta thalassemia, a rare blood disorder. The awards are a product of the…
-
Injectable Therapy for Rotator Cuff Injuries in Development
Biomedical engineers at Georgia Institute of Technology in Atlanta are developing a material to be injected into torn rotator cuff tendons, a common sports injury, to speed their healing. The five-year project is led by Georgia Tech’s biomedical engineering professor Johnna Temenoff and funded by a $1 million grant from National Institute of Arthritis and…
-
Start-Up Licenses UMass Cancer Immunotherapy Technology
Agalimmune Ltd., a new start-up enterprise in London, U.K. and Irvine, California, licensed research discoveries from University of Massachusetts Medical School in Worcester to develop treatments for solid tumors that harness the power of the patient’s immune system. Financial details of the agreement were not disclosed. The technology licensed from UMass, called Alphaject by the…
-
Immunotherapy Shown Effective in Brain Tumor Animal Test
Researchers at University of Zurich in Switzerland tested a therapy in lab mice that harnesses the immune system to fight glioblastoma, an aggressive form of brain cancer. The team led by Zurich immunologist Burkhard Becher reported its findings yesterday online in the Journal of Experimental Medicine (paid subscription required) and seeks commercial partners for accelerated…
-
Genome Editing Start-Up Secures $43M in First Round Funds
The Cambridge, Massachusetts start-up Editas Medicine, developing therapies based on new research in genome editing, gained $43 million in its first financing round. The funding was led by venture companies Flagship Ventures, Polaris Partners, and Third Rock Ventures, with participation from Partners Innovation Fund, the venture funding arm of Massachusetts General Hospital and Brigham and…
-
Nanoparticles, Ultrasound Offer Option to Insulin Injections
Biomedical engineers at North Carolina State University in Raleigh developed a system of long-term insulin delivery for patients with diabetes, which tests in lab animals show can regulate blood glucose levels without painful injections. The team led by NC State engineering professor Zhen Gu published its findings online earlier this week in the journal Advanced…
-
Gene Therapy Shows Long-Term Benefit for Heart Failure
A therapy using genes to induce production of an enzyme for heart cells to restore their use of calcium was found to help heart failure patients in a clinical trial reduce their incidents of cardiac problems over a three-year period. Researchers at Mount Sinai Health System in New York, with colleagues from the biotechnology company…
-
Inflammation Drug Biotech Lands $32.4M in Venture Funding
Catabasis Pharmaceuticals Inc., a clinical-stage biotechnology company in Cambridge, Massachusetts, completed its second venture funding round, securing $32.4 million. The round was led by new investor Lightstone Ventures, with participation by the company’s current investors: SV Life Sciences, Clarus Ventures, MedImmune Ventures, and Advanced Technology Ventures. Catabasis Pharmaceuticals develops medications to treat cardiovascular, metabolic and inflammatory…
-
Roche, Biotech Ink Cancer Vaccine/Immunotherapy Deal
The company immatics biotechnologies GmbH in Tuebingen, Germany and the global pharmaceutical maker Roche will collaborate on discovery and development of cancer vaccines and therapies that harness the human immune system. The deal will provide immatics (spelled in all lower case) an immediate payment of $17 million, but future payments to the company could reach…
-
Cancer Genomics Precision-Medicine Center Opens in Boston
A group of research institutes and hospitals in Boston is opening a new lab to study the science leading to individualized cancer therapies based on the genomic make-up of a patient’s tumors. The Joint Center for Cancer Precision Medicine is a collaboration of Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the…